Marta Schirripa
About
Marta Schirripa is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Marta Schirripa has authored 125 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Oncology, 49 papers in Pulmonary and Respiratory Medicine and 36 papers in Cancer Research. Recurrent topics in Marta Schirripa's work include Colorectal Cancer Treatments and Studies (94 papers), Cancer Treatment and Pharmacology (30 papers) and Lung Cancer Treatments and Mutations (29 papers). Marta Schirripa is often cited by papers focused on Colorectal Cancer Treatments and Studies (94 papers), Cancer Treatment and Pharmacology (30 papers) and Lung Cancer Treatments and Mutations (29 papers). Marta Schirripa collaborates with scholars based in Italy, United States and Japan. Marta Schirripa's co-authors include Fotios Loupakis, Chiara Cremolini, Alfredo Falcone, Lisa Salvatore, Gianluca Masi, Sara Lonardi, Heinz‐Josef Lenz, Francesca Bergamo, Carlotta Antoniotti and Vittorina Zagonel and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and PLoS ONE.
In The Last Decade
Marta Schirripa
117 papers receiving 1.9k citations
Peers
Marta Schirripa
Eiji Shinozaki Japan
Fortunato Ciardiello Italy
Nobuyuki Mizunuma Japan
Jenny F. Seligmann United Kingdom
Bart Jacobs Netherlands
Florence Le Pessot France
Loredana Vecchione Italy
Guillem Argilés Spain
Lorenzo Fornaro Italy
Cees J. van Groeningen Netherlands
Citations per year, relative to Marta Schirripa Marta Schirripa (= 1×)
peers
Eiji Shinozaki
Countries citing papers authored by Marta Schirripa
Since
Specialization
Citations
This map shows the geographic impact of Marta Schirripa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marta Schirripa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marta Schirripa more than expected).
Fields of papers citing papers by Marta Schirripa
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Marta Schirripa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marta Schirripa. The network helps show where Marta Schirripa may publish in the future.
Co-authorship network of co-authors of Marta Schirripa
This figure shows the co-authorship network connecting the top 25 collaborators of Marta Schirripa. A scholar is included among the top collaborators of Marta Schirripa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marta Schirripa. Marta Schirripa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Basso, Michele, Carlo Signorelli, Maria Alessandra Calegari, et al.. (2024). Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis. Targeted Oncology. 19(3). 371–382.
2.
Nelli, Fabrizio, Agnese Fabbri, Diana Giannarelli, et al.. (2023). Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study. Current Oncology. 30(5). 5103–5115.
3.
Formica, Vincenzo, Cristina Morelli, Veronica Conca, et al.. (2023). Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer—A Multicentre Propensity-Score-Matched Retrospective Analysis. Cancers. 15(11). 3064–3064.
4.
Calegari, Maria Alessandra, Michele A. Basso, Alessandro Minelli, et al.. (2023). 617P Predictive and prognostic impact of primary tumor location on sequential treatment with regorafenib and trifluridine/tipiracil at third line and beyond in metastatic colorectal cancer: A real-world multicenter retrospective analysis. Annals of Oncology. 34. S442–S443.
5.
Nelli, Fabrizio, Carlo Signorelli, Agnese Fabbri, et al.. (2023). Changes in Peripheral Immune Cells after the Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine and Disease Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Prospective Analysis of the Vax-on-Third-Profile Study. Cancers. 15(14). 3625–3625.
6.
Nelli, Fabrizio, Diana Giannarelli, Agnese Fabbri, et al.. (2023). Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors. Cancer Immunology Immunotherapy. 72(10). 3217–3228.
7.
Rizzato, Mario Domenico, Monica Niger, Lorenzo Fornaro, et al.. (2023). P-343 The impact of genomic alterations on response rate and survival outcomes in advanced BTC patients who receive cisplatin/gemcitabine plus durvalumab in clinical practice. Annals of Oncology. 34. S135–S135.
8.
Signorelli, Carlo, Marta Schirripa, Mario Giovanni Chilelli, et al.. (2023). Sequential treatment with regorafenib and trifluridine/tipiracil in later-line refractory metastatic colorectal cancer: A real-world multicenter retrospective study.. Journal of Clinical Oncology. 41(4_suppl). 45–45.
9.
Ruggeri, Enzo Maria, Fabrizio Nelli, Agnese Fabbri, et al.. (2021). Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study. ESMO Open. 7(1). 100350–100350.
10.
Pasqualetti, Giuseppe, Marta Schirripa, Matteo Fassan, et al.. (2020). Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial. European Journal of Cancer. 133. 66–73.
11.
Fanelli, Giuseppe Nicolò, Ilaria Depetris, Marta Schirripa, et al.. (2020). The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer. Cancer Cell International. 20(1). 30–30.
12.
Schirripa, Marta, Beatrice Borelli, Romina D’Aurizio, et al.. (2019). Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib. The Pharmacogenomics Journal. 19(5). 455–464.
13.
Schirripa, Marta, Giuseppe Pasqualetti, Riccardo Giampieri, et al.. (2018). Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study. Clinical Colorectal Cancer. 17(3). e601–e615.
14.
Battaglin, Francesca, Alberto Puccini, Rossana Intini, et al.. (2018). The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Review of Anticancer Therapy. 18(3). 251–266.
15.
Hanna, Diana L., Fotios Loupakis, Dongyun Yang, et al.. (2018). Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. Clinical Colorectal Cancer. 17(3). e471–e488.
16.
Berger, Martin D., Sebastian Stintzing, Volker Heinemann, et al.. (2017). A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. Clinical Cancer Research. 24(4). 784–793.
17.
Berger, Martin D., Sebastian Stintzing, Volker Heinemann, et al.. (2017). Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. Annals of Oncology. 28(11). 2780–2785.
18.
Schirripa, Marta, Fotios Loupakis, Cecilia Lando, et al.. (2017). Potential contribution of the study nurse to colorectal cancer (CRC) translational research. Annals of Oncology. 28. vi110–vi110.
19.
Salvatore, Lisa, Fotios Loupakis, Chiara Cremolini, et al.. (2012). Folfoxiri plus Bevacizumab as first-line treatment of BRAF mutant metastatic colorectal cancer patients.. Annals of Oncology. 23.
20.
Loupakis, Fotios, Annamaria Ruzzo, Lisa Salvatore, et al.. (2011). Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer. 11(1). 247–247.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Eiji Shinozaki Breakdown of academic impact, for papers by Fortunato Ciardiello Breakdown of academic impact, for papers by Nobuyuki Mizunuma Breakdown of academic impact, for papers by Jenny F. Seligmann Breakdown of academic impact, for papers by Bart Jacobs Breakdown of academic impact, for papers by Florence Le Pessot Breakdown of academic impact, for papers by Loredana Vecchione Breakdown of academic impact, for papers by Guillem Argilés Breakdown of academic impact, for papers by Lorenzo Fornaro Breakdown of academic impact, for papers by Cees J. van Groeningen